EE165 Cost-Effectiveness Analysis of Liposomal Formulation of Daunorubicin and Cytarabine (CPX-351) for the Treatment of Adult Patients With Newly Diagnosed Therapy-Related AML or AML With Myelodysplasia-Related Changes in Greece

Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.415
https://www.valueinhealthjournal.com/article/S1098-3015(22)02619-5/fulltext
Title : EE165 Cost-Effectiveness Analysis of Liposomal Formulation of Daunorubicin and Cytarabine (CPX-351) for the Treatment of Adult Patients With Newly Diagnosed Therapy-Related AML or AML With Myelodysplasia-Related Changes in Greece
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02619-5&doi=10.1016/j.jval.2022.09.415
First page :
Section Title :
Open access? : No
Section Order : 12222
Categories :
Tags :
Regions :
ViH Article Tags :